Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment

Abstract Immune checkpoint inhibitors (ICIs) have significantly improved the five-year survival rate for advanced melanoma. However, many patients exhibit resistance to ICI therapy. This study evaluated the efficacy and prognostic factors of anti-PD-1 (Group A) and nivolumab–ipilimumab (Group B) the...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, Fatma Pinar Açar, Salih Tünbekici, Gülçin Çelebi, Burçak Karaca
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Springer 2024-12-01
Edice:	Discover Oncology
Témata:	Advanced melanoma Resistance to ICI therapy RMH score Survival
On-line přístup:	https://doi.org/10.1007/s12672-024-01702-w
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!